<p>Cerus（纳斯达克代码：CERS - 获取免费报告）于周四公布了季度财报。这家生物技术公司报告本季度每股收益为（$0.01），超出分析师一致预期的（$0.03）$0.02，FiscalAI 报道。该公司本季度的收入为 5989 万美元，而分析师预期为 5568 万美元。Cerus 的股本回报率为负 26.09%，净利润率为负 7.58%。</p>
<p>以下是 Cerus 电话会议的关键要点：</p>
<ul>
<li>Cerus 将 2026 年全年产品收入指引上调至 <strong>2.27 亿–2.31 亿美元</strong>，IFC 收入指引上调至 <strong>2200 万–2400 万美元</strong>，此前第一季度产品收入为 5370 万美元，同比增长 24%，主要受血小板强度和美国 IFC 需求加速推动。</li>
<li>第一季度毛利率下降至 52%（去年为 58.8%），管理层现在预计 2026 年毛利率将保持在 <strong>低 50%</strong>，原因是持续的通货膨胀、关税和外汇压力。</li>
<li>非 GAAP 调整后的 EBITDA 在第一季度为正 <strong>400 万美元</strong>（连续第八个季度），GAAP 净亏损缩小至 160 万美元，公司在季度末现金余额为 8040 万美元，同时指出与库存增长相关的 300 万美元的运营现金使用。</li>
<li>短期内的监管和产品催化剂包括本季度对 INT100/INT200 的美国 PMA 提交（INT200 计划于 2027 年上半年推出）以及 2026 年第四季度红细胞项目的第三阶段 RedeS 结果，预计将于 2027 年初进入 CE 标记路径。</li>
<li>商业势头包括来自 <strong>BCA 协议</strong> 的早期进展（接触到约 50% 的美国血液供应）、与法国 EFS 的多年续约，以及管理层预计将扩大覆盖面并支持利润率扩张的基于套件的 IFC 销售的持续转变。</li>
</ul>
<h2>Cerus 股价上涨 5.7%</h2>
<p>周四，Cerus 股票交易上涨 0.11 美元，达到 2.03 美元。该公司交易了 965,608 股，较其平均交易量 958,775 股有所增加。该公司的债务与股本比率为 0.62，流动比率为 1.73，速动比率为 1.17。该公司的市值为 4.0675 亿美元，市盈率为-25.38，贝塔值为 1.63。该公司的 50 日移动平均价格为 1.97 美元，200 日移动平均价格为 1.98 美元。Cerus 的 1 年最低价为 1.15 美元，1 年最高价为 2.96 美元。</p>
<h2>Cerus 内部买卖情况</h2>
<p>在相关消息中，首席财务官 Kevin Dennis Green 于 3 月 12 日（星期四）出售了 127,544 股公司的股票，交易价格为每股平均 1.66 美元，总交易额为 211,723.04 美元。交易完成后，首席财务官持有公司 1,040,551 股，价值约为 1,727,314.66 美元。此次交易使其持股减少了 10.92%。该出售在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，内部人士 Richard J. Benjamin 于 3 月 12 日（星期四）出售了 101,740 股股票，交易价格为每股平均 1.66 美元，总交易额为 168,888.40 美元。交易完成后，该内部人士持有公司 777,361 股，价值约为 1,290,419.26 美元。此次交易使其持股减少了 11.57%。该出售的披露可在 SEC 文件中找到。在过去的九十天里，内部人士已出售价值 2,106,290 美元的 1,194,282 股公司股票。5.60% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>最近，一些对冲基金和其他机构投资者增加或减少了对 CERS 的持股。Captrust Financial Advisors 在第四季度将其在 Cerus 的持股增加了 15.3%。Captrust Financial Advisors 目前持有 37,051 股生物技术公司的股票，价值 76,000 美元，此前在上个季度增持了 4,916 股。Engineers Gate Manager LP 在第四季度将其在 Cerus 的持股增加了 4.7%。Engineers Gate Manager LP 目前持有 142,958 股生物技术公司的股票，价值 294,000 美元，此前在上个季度增持了 6,415 股。Intech Investment Management LLC 在第三季度将其在 Cerus 的持股增加了 8.6%。Intech Investment Management LLC 目前持有 93,343 股生物技术公司的股票，价值 148,000 美元，此前在该期间增持了 7,355 股。Caitong International Asset Management Co. Ltd 在第四季度将其在 Cerus 的持股增加了 68.4%。Caitong International Asset Management Co. Ltd 目前持有 18,712 股生物技术公司的股票，价值 39,000 美元，此前在上个季度增持了 7,603 股。最后，Alliancebernstein L.P.在第三季度将其在 Cerus 的持股增加了 3.4%。Alliancebernstein L.P.目前持有 231,721 股生物技术公司的股票，价值 368,000 美元，此前在上个季度增持了 7,663 股。78.37% 的股票目前由机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>几位研究分析师最近对该股票发布了报告。TD Cowen 在 1 月 12 日的研究报告中重申了对 Cerus 股票的 “买入” 评级。Zacks Research 在 3 月 12 日的报告中将 Cerus 的评级从 “持有” 下调至 “强烈卖出”。Weiss Ratings 在 3 月 25 日的研究报告中重申了对 Cerus 股票的 “卖出（d-）” 评级。最后，Wall Street Zen 在 3 月 7 日的报告中将 Cerus 的评级从 “买入” 下调至 “持有”。一位分析师对该股票给予了买入评级，两位分析师对该公司给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “减持”。</p>
<p><strong>查看我们最新的 CERS 股票报告</strong></p>
<h2>Cerus 公司简介</h2>
<p>（获取免费报告）</p>
<p>Cerus Corporation 是一家生物医学产品公司，致力于提升全球输血的安全性。其旗舰产品 INTERCEPT 血液系统采用病原体去活化技术，旨在灭活捐献的血小板和血浆中的广泛病毒、细菌和寄生虫。这种方法旨在降低输血传播感染的风险，提高患者血液成分的安全性。</p>
<p>INTERCEPT 平台无缝集成到现有的血液中心工作流程中，为收集的血液产品提供一步治疗过程。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而 Cerus 不在其中</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 Cerus 1,000 美元吗？</h2>
<p>在考虑 Cerus 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 Cerus 不在名单上。</p>
<p>尽管 Cerus 目前在分析师中被评为减持评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CERS

<p>Cerus (NASDAQ:CERS) 报告季度收益为每股亏损 ($0.01)，超出预期 $0.02。收入达到 5989 万美元，超过了 5568 万美元的预测。该公司将 2026 年的产品收入指引上调至 2.27 亿至 2.31 亿美元。尽管净利润率为负 7.58%，股本回报率为 -26.09%，Cerus 仍实现了 400 万美元的正向非 GAAP 调整后 EBITDA。股价上涨 5.7%，至 2.03 美元。公司高管进行了股票出售，首席财务官 Kevin Dennis Green 出售了 127,544 股。机构投资者最近也调整了在 Cerus 的持股</p>

<p>Cerus (NASDAQ:CERS - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02, FiscalAI reports. The firm had revenue of $59.89 million during the quarter, compared to analyst estimates of $55.68 million. Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%.</p>
<div class="lb-trans"><p>Cerus（纳斯达克代码：CERS - 获取免费报告）于周四公布了季度财报。这家生物技术公司报告本季度每股收益为（$0.01），超出分析师一致预期的（$0.03）$0.02，FiscalAI 报道。该公司本季度的收入为 5989 万美元，而分析师预期为 5568 万美元。Cerus 的股本回报率为负 26.09%，净利润率为负 7.58%。</p>
</div><p>Here are the key takeaways from Cerus' conference call:</p>
<div class="lb-trans"><p>以下是 Cerus 电话会议的关键要点：</p>
</div><ul>
<li>Cerus raised full‑year 2026 product revenue guidance to <strong>$227M–$231M</strong> and IFC revenue to <strong>$22M–$24M</strong> after Q1 product revenue of $53.7M, up 24% year‑over‑year driven by platelet strength and accelerating U.S. IFC demand.</li>
<li>First‑quarter gross margin declined to 52% (from 58.8% a year ago) and management now expects 2026 gross margin to remain in the <strong>low‑50s</strong> due to persistent inflation, tariffs, and foreign‑exchange headwinds.</li>
<li>Non‑GAAP adjusted EBITDA was positive <strong>$4M</strong> in Q1 (the eighth consecutive quarter), GAAP net loss narrowed to $1.6M, and the company ended the quarter with $80.4M in cash while noting a $3M operational cash use tied to inventory builds for growth.</li>
<li>Near‑term regulatory and product catalysts include a U.S. PMA submission for the INT100/INT200 this quarter (INT200 launch targeted in H1 2027) and a Phase III RedeS readout for the Red Blood Cell program in Q4 2026 with a likely CE‑mark pathway into early 2027.</li>
<li>Commercial momentum includes early traction from the <strong>BCA agreement</strong> (access to ~50% of U.S. blood supply), a multi‑year renewal with France’s EFS, and an ongoing shift toward kit‑based IFC sales that management expects will broaden reach and support margin expansion.</li>
</ul>
<div class="lb-trans"><ul>
<li>Cerus 将 2026 年全年产品收入指引上调至 <strong>2.27 亿–2.31 亿美元</strong>，IFC 收入指引上调至 <strong>2200 万–2400 万美元</strong>，此前第一季度产品收入为 5370 万美元，同比增长 24%，主要受血小板强度和美国 IFC 需求加速推动。</li>
<li>第一季度毛利率下降至 52%（去年为 58.8%），管理层现在预计 2026 年毛利率将保持在 <strong>低 50%</strong>，原因是持续的通货膨胀、关税和外汇压力。</li>
<li>非 GAAP 调整后的 EBITDA 在第一季度为正 <strong>400 万美元</strong>（连续第八个季度），GAAP 净亏损缩小至 160 万美元，公司在季度末现金余额为 8040 万美元，同时指出与库存增长相关的 300 万美元的运营现金使用。</li>
<li>短期内的监管和产品催化剂包括本季度对 INT100/INT200 的美国 PMA 提交（INT200 计划于 2027 年上半年推出）以及 2026 年第四季度红细胞项目的第三阶段 RedeS 结果，预计将于 2027 年初进入 CE 标记路径。</li>
<li>商业势头包括来自 <strong>BCA 协议</strong> 的早期进展（接触到约 50% 的美国血液供应）、与法国 EFS 的多年续约，以及管理层预计将扩大覆盖面并支持利润率扩张的基于套件的 IFC 销售的持续转变。</li>
</ul>
</div><h2>Cerus Trading Up 5.7%</h2>
<div class="lb-trans"><h2>Cerus 股价上涨 5.7%</h2>
</div><p>Shares of Cerus stock traded up $0.11 during trading on Thursday, hitting $2.03. 965,608 shares of the company were exchanged, compared to its average volume of 958,775. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.73 and a quick ratio of 1.17. The firm has a market capitalization of $406.75 million, a P/E ratio of -25.38 and a beta of 1.63. The firm's fifty day moving average price is $1.97 and its 200 day moving average price is $1.98. Cerus has a 1-year low of $1.15 and a 1-year high of $2.96.</p>
<div class="lb-trans"><p>周四，Cerus 股票交易上涨 0.11 美元，达到 2.03 美元。该公司交易了 965,608 股，较其平均交易量 958,775 股有所增加。该公司的债务与股本比率为 0.62，流动比率为 1.73，速动比率为 1.17。该公司的市值为 4.0675 亿美元，市盈率为-25.38，贝塔值为 1.63。该公司的 50 日移动平均价格为 1.97 美元，200 日移动平均价格为 1.98 美元。Cerus 的 1 年最低价为 1.15 美元，1 年最高价为 2.96 美元。</p>
</div><h2>Insider Buying and Selling at Cerus</h2>
<div class="lb-trans"><h2>Cerus 内部买卖情况</h2>
</div><p>In related news, CFO Kevin Dennis Green sold 127,544 shares of the business's stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $1.66, for a total transaction of $211,723.04. Following the completion of the transaction, the chief financial officer owned 1,040,551 shares in the company, valued at approximately $1,727,314.66. The trade was a 10.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, insider Richard J. Benjamin sold 101,740 shares of the stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $1.66, for a total transaction of $168,888.40. Following the completion of the sale, the insider owned 777,361 shares in the company, valued at approximately $1,290,419.26. This trade represents a 11.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,194,282 shares of company stock worth $2,106,290 over the last ninety days. 5.60% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Kevin Dennis Green 于 3 月 12 日（星期四）出售了 127,544 股公司的股票，交易价格为每股平均 1.66 美元，总交易额为 211,723.04 美元。交易完成后，首席财务官持有公司 1,040,551 股，价值约为 1,727,314.66 美元。此次交易使其持股减少了 10.92%。该出售在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，内部人士 Richard J. Benjamin 于 3 月 12 日（星期四）出售了 101,740 股股票，交易价格为每股平均 1.66 美元，总交易额为 168,888.40 美元。交易完成后，该内部人士持有公司 777,361 股，价值约为 1,290,419.26 美元。此次交易使其持股减少了 11.57%。该出售的披露可在 SEC 文件中找到。在过去的九十天里，内部人士已出售价值 2,106,290 美元的 1,194,282 股公司股票。5.60% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in CERS. Captrust Financial Advisors increased its holdings in shares of Cerus by 15.3% in the fourth quarter. Captrust Financial Advisors now owns 37,051 shares of the biotechnology company's stock worth $76,000 after acquiring an additional 4,916 shares in the last quarter. Engineers Gate Manager LP lifted its holdings in shares of Cerus by 4.7% during the 4th quarter. Engineers Gate Manager LP now owns 142,958 shares of the biotechnology company's stock valued at $294,000 after purchasing an additional 6,415 shares in the last quarter. Intech Investment Management LLC grew its position in shares of Cerus by 8.6% in the 3rd quarter. Intech Investment Management LLC now owns 93,343 shares of the biotechnology company's stock valued at $148,000 after purchasing an additional 7,355 shares during the period. Caitong International Asset Management Co. Ltd increased its stake in Cerus by 68.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 7,603 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in Cerus by 3.4% during the 3rd quarter. Alliancebernstein L.P. now owns 231,721 shares of the biotechnology company's stock worth $368,000 after purchasing an additional 7,663 shares in the last quarter. 78.37% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>最近，一些对冲基金和其他机构投资者增加或减少了对 CERS 的持股。Captrust Financial Advisors 在第四季度将其在 Cerus 的持股增加了 15.3%。Captrust Financial Advisors 目前持有 37,051 股生物技术公司的股票，价值 76,000 美元，此前在上个季度增持了 4,916 股。Engineers Gate Manager LP 在第四季度将其在 Cerus 的持股增加了 4.7%。Engineers Gate Manager LP 目前持有 142,958 股生物技术公司的股票，价值 294,000 美元，此前在上个季度增持了 6,415 股。Intech Investment Management LLC 在第三季度将其在 Cerus 的持股增加了 8.6%。Intech Investment Management LLC 目前持有 93,343 股生物技术公司的股票，价值 148,000 美元，此前在该期间增持了 7,355 股。Caitong International Asset Management Co. Ltd 在第四季度将其在 Cerus 的持股增加了 68.4%。Caitong International Asset Management Co. Ltd 目前持有 18,712 股生物技术公司的股票，价值 39,000 美元，此前在上个季度增持了 7,603 股。最后，Alliancebernstein L.P.在第三季度将其在 Cerus 的持股增加了 3.4%。Alliancebernstein L.P.目前持有 231,721 股生物技术公司的股票，价值 368,000 美元，此前在上个季度增持了 7,663 股。78.37% 的股票目前由机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research analysts have recently issued reports on the stock. TD Cowen reaffirmed a &#34;buy&#34; rating on shares of Cerus in a research note on Monday, January 12th. Zacks Research lowered shares of Cerus from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a report on Thursday, March 12th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Cerus in a research note on Wednesday, March 25th. Finally, Wall Street Zen lowered shares of Cerus from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, March 7th. One analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of &#34;Reduce&#34;.</p>
<div class="lb-trans"><p>几位研究分析师最近对该股票发布了报告。TD Cowen 在 1 月 12 日的研究报告中重申了对 Cerus 股票的 “买入” 评级。Zacks Research 在 3 月 12 日的报告中将 Cerus 的评级从 “持有” 下调至 “强烈卖出”。Weiss Ratings 在 3 月 25 日的研究报告中重申了对 Cerus 股票的 “卖出（d-）” 评级。最后，Wall Street Zen 在 3 月 7 日的报告中将 Cerus 的评级从 “买入” 下调至 “持有”。一位分析师对该股票给予了买入评级，两位分析师对该公司给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “减持”。</p>
</div><p><strong>Check Out Our Latest Stock Report on CERS</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 CERS 股票报告</strong></p>
</div><h2>Cerus Company Profile</h2>
<div class="lb-trans"><h2>Cerus 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.</p>
<div class="lb-trans"><p>Cerus Corporation 是一家生物医学产品公司，致力于提升全球输血的安全性。其旗舰产品 INTERCEPT 血液系统采用病原体去活化技术，旨在灭活捐献的血小板和血浆中的广泛病毒、细菌和寄生虫。这种方法旨在降低输血传播感染的风险，提高患者血液成分的安全性。</p>
</div><p>The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.</p>
<div class="lb-trans"><p>INTERCEPT 平台无缝集成到现有的血液中心工作流程中，为收集的血液产品提供一步治疗过程。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Cerus</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而 Cerus 不在其中</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CERS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cerus Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 Cerus 1,000 美元吗？</h2>
</div><p>Before you consider Cerus, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Cerus 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cerus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 Cerus 不在名单上。</p>
</div><p>While Cerus currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Cerus 目前在分析师中被评为减持评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cerus（纳斯达克代码：CERS）公布季度财报，每股收益比预期高出 0.02 美元